BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
BioAge Labs, Inc.NASDAQ: BIOA
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$355.67M, compared with -$265.74M a year earlier.
Context
- Retained earnings amounted to 89.4% of total assets at the end of Q1 FY2026, up 12.2 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -33.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (333.42M) USD
- Year-over-year change
- -31.9%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (333.42M) | -31.9% |
| FY2024 | 2024-12-31 | (252.81M) | -39.1% |
| FY2023 | 2023-12-31 | (181.7M) | -54.2% |
| FY2022 | 2022-12-31 | (117.85M) | — |
Retained Earnings vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -33.8% is the 7th highest of 9, against a peer median of -11.6%.
- Retained earnings amounts to 89.4% of total assets for BIOA, versus a peer median of 518.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$140.35M USD | -13.9% | — | 142.3% | |
| Dec 2025 | -$223.2M USD | — | — | 96.1% | |
BIOABioAge Labs, Inc. | Mar 2026 | -$355.67M USD | -33.8% | — | 89.4% |
| Mar 2026 | -$560.47M USD | -45.6% | — | 378.3% | |
| Mar 2026 | -$568.01M USD | -42.5% | — | 212.7% | |
| Mar 2026 | -$744.47M USD | -15.1% | — | 673.4% | |
| Mar 2026 | -$1.65B USD | -7.1% | — | 1107.2% | |
| Mar 2026 | -$2.05B USD | -9.2% | — | 518.6% | |
| Mar 2026 | -CA$6.46B CAD | -2.0% | — | 1071.7% | |
| Mar 2026 | -CA$11.14B CAD | -1.9% | — | 995.6% | |
| Peer median (excluding BIOA) | — | -11.6% | — | 518.6% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.